A3 Cell Line | CL-0315

A3 Cell Line | CL-0315 | Gentaur US, UK & Europe Disrtribition

Media: CM-0315

Organism: Homo sapiens, Human

Application: N/A

Background: The Jurkat cells were treated with Fas Antibody and isolated by limiting dilution to obtain a cell line that had a low spontaneous rate of resistance to Fas-medicated apoptosis. The resulting wild-type A3 subclone is very sensitive to Fas-mediated apoptosis. Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Two of these ICR-191 treated clones have been deposited at the ATCC. They are I 9. 2, a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2. 1, a clone with a mutation in the adaptor FADD.

Age: N/A

Tissue: Peripheral blood

Morphology: Lymphoblast

Growth Properties: Suspension

Doubling Time: N/A

Biosafty: 1

Medium: RPMI-1640(PM150110)+10% FBS+1% P/S(PB180120)

Subculturing: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2×10^5 viable cells/ml. Maintain cell density between 1×10^5 and 1×10^6 viable cells/ml.

Ratio: 1:2 to 1:4

Renewal: Every 2 to 3 days

Cryopreservation: Freeze medium: 60% Basal medium+30% FBS+10% DMSO Storage temperature: Liquid nitrogen vapor phase

Culture Conditions: Atmosphere: Air, 95%; CO2, 5% Temperature: 37℃

Effects: N/A

Duration: N/A

Lead Time: 3-5 days